Inflammatory Cytokine Levels After Endovascular Therapy in Patients With Peripheral Artery Disease

Abstract

We evaluated the impact of endovascular therapy (EVT) on inflammatory cytokine levels and its relationship with in-stent restenosis in patients with peripheral artery disease. The study prospectively enrolled 35 patients with intermittent claudication who underwent EVT of the iliofemoral artery. Levels of interleukin 6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and tumor necrosis factor α (TNF-α) were measured using enzyme-linked immunosorbent assay before and at 2 hours, 4 hours, and 3 months after EVT. All cytokine levels increased significantly after EVT (IL-6 [pg/mL]: from 1.51 [0.84-1.93] before EVT to 6.97 [4.05-20.41] at 2 hours and 13.29 [4.57-31.88] at 4 hours; MCP-1 [pg/mL]: from 326.65 [265.60-406.55] before EVT to 411.18 [341.21-566.27] at 2 hours and 519.36 [383.58-644.85] at 4 hours; TNF-α [pg/mL]: from 1.08 [0.77-1.29] before EVT to 1.25 [0.94-1.81] at 2 hours and 1.27 [0.95-1.59] at 4 hours, all P < .001). However, cytokine levels did not differ significantly between lesions with and without in-stent restenosis. Overall, our results suggest that EVT significantly increases IL-6, MCP-1, and TNF-α levels in the ischemic leg, but this effect is not associated with a higher rate of in-stent restenosis.

Keywords

peripheral artery disease cytokine interleukin 6 endovascular therapy

Get full access to this article

View all access options for this article.

References

Ikeda

Ohkawa

Seino

. et al. Serum interleukin 6 levels become elevated in acute myocardial infarction. J Mol Cell Cardiol. 1992;24(6):579–584.

Neumann

Ott

Gawaz

. et al. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation. 1995;92(4):748–755.

Biasucci

Liuzzo

Grillo

. et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation. 1999;99(7):855–860.

Hoogeveen

Morrison

Boerwinkle

. et al. Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study. Atherosclerosis. 2005;183(2):301–307.

Cesari

Penninx

Newman

. et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation. 2003;108(19):2317–2322.

Tzoulaki

Murray

Lee

Rumley

Lowe

Fowkes

. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation. 2005;112(7):976–983.

Criqui

Langer

Fronek

. et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326(6):381–386.

Barani

Nilsson

Mattiasson

Lindblad

Gottsäter

. Inflammatory mediators are associated with 1-year mortality in critical limb ischemia. J Vasc Surg. 2005;42(1):75–80.

Greenland

Abrams

Aurigemma

. et al. Prevention Conference V: beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. Circulation. 2000;101(1):E16–E22.

10.

Ranke

Creutzig

Alexander

. Duplex scanning of the peripheral arteries: correlation of the peak velocity ratio with angiographic diameter reduction. Ultrasound Med Biol. 1992;18(5):433–440.

11.

Dinarello

. Biologic basis for interleukin-1 in disease. Blood. 1996;87(6):2095–2147.

12.

Hirano

. Interleukin 6 and its receptor: ten years later. Int Rev Immunol. 1998;16(3-4):249–284.

13.

Yan

Tritto

Pinsky

. et al. Induction of interleukin 6 (IL-6) by hypoxia in vascular cells. Central role of the binding site for nuclear factor-IL-6. J Biol Chem. 1995;270(19):11463–11471.

14.

Gwechenberger

Mendoza

Youker

. et al. Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. Circulation. 1999;99(4):546–551.

15.

Inoue

Sakai

Morooka

Hayashi

Takayanagi

Takabatake

. Expression of polymorphonuclear leukocyte adhesion molecules and its clinical significance in patients treated with percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1996;28(5):1127–1133.

16.

Lee

Stabile

Kinnaird

. et al. Temporal patterns of gene expression after acute hindlimb ischemia in mice: insights into the genomic program for collateral vessel development. J Am Coll Cardiol. 2004;43(3):474–482.

17.

Pietersma

Kofflard

de Wit

. et al. Late lumen loss after coronary angioplasty is associated with the activation status of circulating phagocytes before treatment. Circulation. 1995;91(5):1320–1325.

18.

Hojo

Ikeda

Katsuki

. et al. Interleukin 6 expression in coronary circulation after coronary angioplasty as a risk factor for restenosis. Heart. 2000;84(1):83–87.

19.

Hojo

Ikeda

Katsuki

. et al. Chemokine expression in coronary circulation after coronary angioplasty as a prognostic factor for restenosis. Atherosclerosis. 2001;156(1):165–170.

20.

Schillinger

Sabeti

Loewe

. et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354(18):1879–1888.

21.

Soga

Iida

Hirano

. et al. Utility of new classification based on clinical and lesional factors after self-expandable nitinol stenting in the superficial femoral artery. J Vasc Surg. 2011;54(4):1058–1066.

22.

Ebisawa

Kashima

Miyashita

. et al. Impact of endovascular therapy on oxidative stress in patients with peripheral artery disease. Circ J. 2014;78(6):1445–1450.